| Document |
Document Title |
|
JP3180855B2 |
PURPOSE: To provide a cockroach-collecting pheromone comprising a cockroach- attracting substance and a cockroach-restraining substance and useful as a cockroach-controlling agent extremely excellent in its controlling effect because of ...
|
|
JP2001508040A |
A method of lowering plasma levels of Lp(a) or inhibiting the generation of apo(a) in a human by administering an effective amount of a compound of formula (I): (I) wherein: R1 is hydrogen or alkyl; A, B, D, E, G, R2 and R3 each are hydr...
|
|
JP2001503732A |
Steroid compounds having various oxygen substitution on the steroid nucleus are disclosed. A specific functionality present on many of the steroid compounds is oxygen substitution at both of positions 6 and 7. Thus, certain steroids have...
|
|
JP2000309599A |
To obtain a new compound exhibiting steroid sulfatase inhibitory activity and useful for the therapy or prophylaxis for hormone dependent diseases. This compound is represented by formula I (R1 is OH, an alkoxy or group NR2R3; R2 are eac...
|
|
JP2000513380A |
There are described therapeutically active compounds or salts or solvates thereof, hydrolysable in human or animal blood to compounds with reduced therapeutic activity. There is also described a method of identifying a compound capable o...
|
|
JP3056770B2 |
Products of general formula (I): in which R1 denotes an aliphatic hydrocarbon radical, R2 and R3, which are identical or different, denote a hydrogen atom or an alkyl radical, G denotes a hydrocarbon group containing from one to eighteen...
|
|
JP3049504B2 |
Angiostatic steroids for use in controlling ocular hypertension are disclosed. Pharmaceutical compositions of the angiostatlc steroids and their use in treating ocular hypertension, including controlling the ocular hypertension associate...
|
|
JP3048636B2 |
PCT No. PCT/EP91/02494 Sec. 371 Date Jun. 22, 1993 Sec. 102(e) Date Nov. 1, 1993 PCT Filed Dec. 21, 1991 PCT Pub. No. WO92/11278 PCT Pub. Date Jul. 9, 1992.Novel compounds of the general formula I (I) and the pharmacologically tolerable ...
|
|
JP3048637B2 |
PCT No. PCT/EP91/02495 Sec. 371 Date Feb. 25, 1994 Sec. 102(e) Date Feb. 25, 1994 PCT Filed Dec. 21, 1991 PCT Pub. No. WO92/11279 PCT Pub. Date Jul. 9, 1992.New D-homo-(16-ene)-11 beta -aryl-4-estrenes of general formula I (I) as well as...
|
|
JP3037427B2 |
Starting compounds for preparing calcitriol (1$g(a), 25-dihydroxycholecalciferol) and its derivatives showing, as compared with calcitriol, some modifications, particularly in the C-17 lateral chain, a method for preparing these starting...
|
|
JP3021818B2 |
PURPOSE: To industirially advantageously obtain the compd. of the subject having 5α-reductase inhibiting activity for the treatment for acne and postatomegaly by allowing a 4,5-epoxy compd. of steroid to react with sodium azide in an in...
|
|
JP2985007B2 |
|
|
JP2956776B2 |
There are provided 13-alkyl-11beta-phenyl-gonanes of formula I (I) wherein Z is an oxygen atom or N-OH; R2 is alpha- or beta-position methyl or ethyl; R1 is selected from heteroaryl radicals, cycloalkyl radicals, cycloalkenyl radicals, a...
|
|
JP2947944B2 |
Compounds of the androstane series are described having general formulaand solvates thereof, in which R1 represents O, S or NH; R2 individually represents OC(=O)C1-6 alkyl; R3 individually represents hydrogen, methyl (which may be in eit...
|
|
JP2911553B2 |
Compounds of the general formula I have been described in which X, R<1>, R<2>, R<3> and R<4> have the meaning stated in the description, as well as processes for the preparation thereof, pharmaceutical products containing these compounds...
|
|
JP2904310B2 |
The present invention relates to the compound of formula (I), (I) also known as 17 beta -N-(2,5-bis(Trifluoromethyl))phenylcarbamoyl-4-aza-5 alpha -androst-1-en-3-one, solvates thereof, its preparation, intermediates used in its preparat...
|
|
JPH10509692A |
The invention relates to novel, androstane steroids which are the ligand semiochemicals which bind to neuroepithelial receptors. The steroids are useful as ligands to neuroepithelial receptors in the human vomeronasal gland to stimulate ...
|
|
JPH10509423A |
The invention relates to estrene steroids, which bind to neuroepithelial cells in the human vomeronasal organ. The steroids are preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically a...
|
|
JP2792876B2 |
PCT No. PCT/DE88/00447 Sec. 371 Date Jan. 16, 1990 Sec. 102(e) Date Jan. 16, 1990 PCT Filed Jul. 15, 1988 PCT Pub. No. WO89/00578 PCT Pub. Date Jan. 26, 1989.New 11 beta phenyl-4,9,15-estratrienes of formula I (I) are described, where X ...
|
|
JPH10507451A |
A process of providing novel compounds of Formula (I), that are useful as 6-azaandrostenone testosterone 5-alpha-reductase inhibitors, from commercially available compounds of Formula (II) +TR wherein the substituents are as defined in t...
|
|
JPH10507176A |
The disclosed invention is a process for preparing 17-beta-substituted-androsta-3,5-dien-3-carboxylic acids from 3-halo-17-beta-substituted-androsta-3,5-dienes. The process may be performed in either of two ways: (1) the 3-halo compound ...
|
|
JP2768864B2 |
PURPOSE: To obtain a new amine compd. as an intermediate of an amine steroid useful in the treatment of medulla spinalis injury, head injury, subarachnoid hemorrhage, asthma, muscular dystrophy, skin graft rejection, septic shock, etc. C...
|
|
JP2718834B2 |
|
|
JPH10501233A |
Invented are 17 alpha and 17 beta -substituted aromatic A ring steroidal synthetic compounds, pharmaceutical compositions containing these compounds, and methods for using these compounds to inhibit steroid 5- alpha -reductase.
|
|
JPH09512270A |
The present invention relates to methods and compositions for the transformation of cells. In particular, compositions and methods are disclosed which include combinations of the nucleic acid of interest and polyhydroxylated or polyglyco...
|
|
JP2687209B2 |
A novel steroid of the formula I wherein X is methylene and R is an optionally substituted carbocyclic aryl or heterocyclic aryl or optionally substituted vinyl or ethynyl or X is a simple bond or -S- and R is optionally substituted carb...
|
|
JP2675418B2 |
Compounds of formula (I) in which X<1>, X<2> and X<3> are hydrogen, halogen, CF3, C1-6alkyl, OH, C1-6alkoxy, CN, NO2, N(R<1>)2, CHO or CO2R<1>; A is O or S, n is 0 or 1, R<1> is H or C1-8alkyl and R<3> is alpha -H, alpha -OH, or alpha -a...
|
|
JP2660404B2 |
1. The products of formula I : see diagramm : EP0245170,P90,F1 in which R1 represents an alkynyl radical having from 2 to 8 carbon atoms optionally substituted by a radical selected from the radicals, hydroxyl, halogen, trialkylsilyl, al...
|
|
JP2657982B2 |
Compounds of formula I formula I where R1, R2, R3, R4, R5, R6, n, and +Z are as defined herein, their use as antiinflammatory, immunosuppressive, and antiallergic agents, pharmaceutical compositions comprising them, and methods for their...
|
|
JP2610674B2 |
PCT No. PCT/US88/02429 Sec. 371 Date Jan. 30, 1990 Sec. 102(e) Date Jan. 30, 1990 PCT Filed Jul. 22, 1988 PCT Pub. No. WO89/01483 PCT Pub. Date Feb. 23, 1989.The invention involves a two step chemical transformation of a steroidal 17-cya...
|
|
JP2604842B2 |
The present invention involves improved processes for the dehalogenation of 9 alpha -halosteroids (I) (I) to produce the corresponding 11 beta -hydroxy steroids (II) (II) which are known to be useful as pharmaceutical, where the improvem...
|
|
JPH09503227A |
PCT No. PCT/EP95/02649 Sec. 371 Date May 31, 1996 Sec. 102(e) Date May 31, 1996 PCT Filed Jul. 7, 1995 PCT Pub. No. WO96/03422 PCT Pub. Date Feb. 8, 1996The present invention provides compounds of formula (D wherein the symbol +E,uns - -...
|
|
JPH09503228A |
The present invention provides a compound of formula (I), wherein A is a bond or a straight or branched C1-C6 alkylene chain; W is a group -R1, -OR2, -NR3R4 or (a) wherein: Y is oxygen or sulphur; R1, R2 and R4 are: a C1-C10 alkyl group,...
|
|
JPH09502982A |
The present invention relates to oligosaccharide-containing 14-aminosteroid compounds and the pharmaceutically-acceptable acid salts or esters thereof of the general formula: wherein a) R1 is (i) COOR5, where R5 is hydrogen, a 1-6 carbon...
|
|
JPH0967393A |
To obtain the subject new compound having 5 α-reductase inhibiting action and useful as a preventing or treating medicine for prostatic hypertrophy from cultured products obtained by culturing dicephalosterol producing bacterium belongi...
|
|
JP2584829B2 |
9(11)-dehydroandrostanes and 9(11)-dehydropregnanes are prepared by dehydrating the corresponding 9-alpha-hydroxy steroid in the presence of a Lewis acid. The corresponding 8(9)-dehydro-isomer was not detectable. The resulting products a...
|
|
JPH09501433A |
The applications discloses the treatment of inflammatory disorders, in particular those associated with rheumatoid, arthritis, gout, gouty arthritis and Behcet's syndrome, with 2-methoxyestradiol.
|
|
JP2550777B2 |
|
|
JPH08291073A |
PURPOSE: To obtain a medicinal composition having a high ratio of attaining to vehicula and a high utilization ratio of an active ingredient, and useful as an antiasthmatic agent by blending fine powder of a specific steroid derivative w...
|
|
JPH08291072A |
PURPOSE: To obtain the subject crystals having a high ratio of attaining to vesicula and a high utilization ratio of an active ingredient, and useful as an antiasthmatic agent by treating fine powder of a specific steroid derivative with...
|
|
JPH08509968A |
Lupane derivatives of general formula (I) in which R is a radical of general formula (II) for which R' is a hydrogen atom or an alkyl radical, X is carbamoyl, N-méthyl carbamoyl, aminocarbonyl or N-methylaminocarbonyl, Y is substituted ...
|
|
JPH08509969A |
Lupane derivatives of general formula (I) in which R is: (II), wherein X is a bond or an optionally substituted carbamoyl or aminocarbonyl, Y is a bond or phenylene, R DEG and R DEG DEG , which are the same or different, are H or methyl ...
|
|
JPH08504825A |
The present invention relates to certain substituted 17 beta -substituted carbonyl-6-azaandrost-4-en-3-ones of formula (I), wherein R<1> and R<2> i) are independently hydrogen or lower alkyl and the bond between the carbons bearing R<1> ...
|
|
JPH08503473A |
Invented are novel 17 alpha -acyl steroidal 5 alpha -reductase inhibiting compounds, pharmaceutical compositions containing these compounds, and methods for using these compounds to inhibit steroid 5- alpha -reductase. Also invented are ...
|
|
JPH08503471A |
Invented are 17 alpha and 17 beta -substituted acyl-3-carboxy-3,5-diene analogues of steroidal synthetic compounds, pharmaceutical compositions containing these compounds, and methods for using these compounds to inhibit steroid 5- alpha...
|
|
JPH0881492A |
To profitably obtain the subject derivative useful as an intermediate for synthesizing steroid compounds and so on through several kinds of intermediates comprising new compounds by allowing a 17-keto-steroid derivative to react with a h...
|
|
JPH0826062B2 |
9-Alpha-hydroxy- steroids (I) contg. a D-ring of formula (A) are new; R2 = ethynyl (provided R5 is not acetoxy if R4 = H), haloethynyl, opt. protected OH, cyano, 1'-Ra-ethenyl; or 1',1'-trimethylene dithio-ethyl; Ra = 1-6C alkoxy or alky...
|
|
JPH0816117B2 |
9 alpha, 11 beta and 11 beta-substituted estranes are disclosed which exhibit elevated estrogenic and postcoital contraceptive activities. A process for their manufacture and their use in pharmaceuticals is also disclosed.
|
|
JPH08500821A |
Invented are 17 alpha and 17 beta -alkylketone-3-carboxy aromatic A ring analogues of steroidal synthetic compounds, pharmaceutical compositions containing these compounds, and methods for using these compounds to inhibit steroid 5- alph...
|
|
JPH07316189A |
PURPOSE: To efficiently obtain the subject new compound usable as a raw material for anti-hypertensive agents by oxidizing and then reducing the unsaturated lactone ring of digitoxigenin-3-acetate with a periodate in the presence of ruth...
|
